Tag Archive for: Pharma

Poolbeg Pharma plc to present POLB 001 pre-clinical study data at the 66th American Society of Hematology (ASH) Annual Meeting

/in

POLB 001 Reduces Cytokine Release Syndrome (CRS) in an in vivo animal model Positive results reinforce POLB 001’s potential in the prevention and treatment of cancer immunotherapy-induced CRS ASH is the world’s premier conference focussing on haematological malignancies 6 November 2024 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development […]

Read more

This week’s hot topic: Why Pharma will have to play the long game on Alzheimer’s drugs

/in

By Stephen Adams, Optimum Strategic Communications Few people expected England and Wales’s drugs spending watchdog, the National Institute for Health and Care Excellence (“NICE”), to approve Eli Lilly’s new dementia drug donanemab for use on the NHS last week.  At a reputed annual cost of at least £60,000 a year, including the care bill, it […]

Read more

Curve Therapeutics further strengthens leadership team with the appointment of Andre Hoekema as new Chair of Board

/in

Dr Hoekema brings over four decades of successful biotech and life science leadership Dr Cora Griffin appointed to head up business development, follows recent appointment of Simon Jones as CFO/COO New hires to accelerate ambition to turbocharge the discovery platform, develop innovative therapeutic pipeline and expand pharma relationships Southampton, UK, 2 October 2024 – Curve […]

Read more

Weekly wrap-up: $100m Series B financing for a bivalent vaccine, to new clinical data from a cutting-edge antibody-drug conjugate…

/in

Vicebio Announces $100 Million Series B Financing and Initiation of Phase 1 Clinical Study of RSV/hMPV Bivalent Vaccine  Vicebio Ltd, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, on Monday announced a $100 million Series B financing  led by TCGX  with investment from Goldman Sachs Alternatives, Avoro Ventures, venBio,  and participation from UniQuest and founding investor Medicxi.  London-based Vicebio said funding […]

Read more

Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei

/in

Stockholm, Sweden, September 3, 2024 – Following the announcement by Asahi Kasei Corporation (“Asahi Kasei”) on September 2, 2024 that it controls more than 90 percent of the outstanding shares of Calliditas Therapeutics AB (Nasdaq: CALT) (“Calliditas” or the “Company”), and declared its offers to purchase all of the outstanding Common Shares and ADSs of Calliditas […]

Read more
© Optimum Strategic Communications.